Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

US FDA, AAMI Consider Device Benefits And Risks In Post-market Phase

This article was originally published in SRA

Executive Summary

Efforts by the US Food and Drug Administration and industry to clarify benefit-risk considerations for medical devices have moved into the post-market space, with the FDA draft guidance and a draft report from a working group led by the Association for the Advancement of Medical Instrumentation (AAMI), both issued on June 151-3.

Advertisement
Advertisement
UsernamePublicRestriction

Register